Official Title
Exploratory Study in COVID-19 During Pregnancy
Brief Summary

The SARS-CoV-2 infection may behave differently in pregnant and postpartum women in theshort and long term. Several risk factors or medication use can interfere on disease'evolution and vertical transmission. Thus, due the current pandemic and the scarcity ofscientific studies involving pregnant women with covid-19 or positive serology, combinedwith the need to elucidate the behavior of this viral infection in pregnant women in ourpopulation, this study aims to evaluate the clinical and laboratory evolution,transplacental passage, gestational and neonatal outcomes in pregnancies with positiveSARS-CoV-2.

Detailed Description

Not Provided

Unknown status
Pregnant Women
COVID19

Diagnostic Test: SARS-CoV-2 serology

Serology test of SARS-CoV-2 for pregnant women

Eligibility Criteria

Inclusion Criteria:

- Pregnant women with clinical symptoms or positive serology for SARS-CoV-2
hospitalized or in delivery time;

- Asymptomatic pregnant women for SARS-CoV-2 during pregnancy and hospitalized for
delivery at HU-USP.

- Pregnant women diagnosed with SARS-CoV-2 prior to delivery and who, after the
quarantine period, followed prenatal care and delivered at the HU-USP or HCFMUSP.

Exclusion Criteria:

- Non-confirmation of maternal SARS-CoV-2 infection in pregnant women hospitalized or
in delivery time.

- Withdrawal of pregnant woman to continue in the study.

Eligibility Gender
Female
Eligibility Age
Minimum: 17 Years ~ Maximum: 50 Years
Countries
Brazil
Locations

Rossana P Fracisco
São Paulo, Brazil

Investigator: Rossana P Francisco, PhD
Contact: +551126616209
rossana.francisco@hc.fm.usp.br

Contacts

Rossana P Francisco, PhD
+551126616209
rossana.francisco@hc.fm.usp.br

Ana Claudia S Farche, PhD
+551126619280
anafarche@usp.br

Rossana P Francisco, PhD, Principal Investigator
Faculdade de Medicina da Universidade de São Paulo - FMUSP

University of Sao Paulo General Hospital
NCT Number
Keywords
pregnancy
SARS-CoV-2
Vertical transmission
MeSH Terms
COVID-19